GTCR-backed Devicor Medical Products has acquired the neoprobe GDS line of gamma detection device systems from Neoprobe (NYSE Amex: NEOP) for $30 million. Neoprobe may also receive up to an additional $20 million in royalties if certain revenue milestones are achieved. Devicor acquires and develops medical device businesses and products. The company received additional equity from GTCR to help fund its purchase of the GDS line.
So far this year, 349 companies have been acquired by PE-backed companies, according to the PitchBook Platform. With a 30% share, the B2B industry has accounted for more of those add-on acquisitions than any other industry, followed by Healthcare (18%) and Information Technology (15%).